Overall verdict
Neutral
5.3/10
1-year performance
-13.85%
Score breakdown
Down 13.8% over 1 year, 9% of the 52-week range.
Strongest: Shareholder return 8.8/10. Weakest: Financial strength 3.2/10.
16 analysts, target +0.2% vs the price.
Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions ;
and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It also offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, and community-based healthcare services, as well as clinical trials services. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Asx
Australia
CEO
James Newcombe
Founded
1934
Employees
49 000
Revenue / employee
223 466 AUD
Next earnings
November 18, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
24.27 AUD
52-week low
18.26 AUD
1-year performance
-13.85%
Declining
Year-to-date performance
-16.36%
Declining
Drawdown
-22.58%
Marked drawdown
Position in the 52-week range
9% of range
Range: 28.34 AUD - 40.68 AUD (comparables only)
The price implies growth of -1.55% per year; the company grows at -10.00%.
Gross margin 27.7%, net margin 5.6%, ROIC 4.6%, ROE 7.3%.
Net margin
5.56%
Exceptional
Sector 3.21%|S&P 12.97%
Gross margin
27.65%
Fair
Return on equity (ROE)
7.30%
Fair
Sector 6.71%|S&P 16.52%
Return on invested capital (ROIC)
4.60%
Fair
Free cash flow margin (FCF)
7.08%
Fair
Profit-to-cash conversion (FCF conversion)
1.27x
Fair
Margin stability
4.4 pts
Steady
Revenue to net income
Growth
4.1/10Revenue up 8.9% over 1 year, 3.7% a year over 5, EPS -14.7% a year over 5.
Revenue (trailing 12 months)
10.9Md AUD
Revenue growth (1y)
8.90%
Solid
Revenue growth (3y)
37.48%
Solid
EPS growth (1y)
21.60%
Solid
EPS CAGR (5y)
-14.75%
Declining
EPS revisions (3 months)
-7.80%
Sharply revised down
Valuation
7.5/10P/E 15.3x, forward P/E 15.6x, EV/EBITDA 7.6x, PEG 1.01. The multiple sits in the 38th percentile of its own 5-year history.
P/E (TTM)
15.3x
Cheap
Sector 30.9x|S&P 23.0x
Forward P/E
15.6x
Fair
EV / EBITDA
7.6x
Cheap
Sector 13.1x|S&P 14.5x
PEG
1.01
Fair
Sector 0.75|S&P 0.86
Fair value (reverse DCF)
34.51 AUD
Deeply undervalued
P/E vs its own 5-year history
among the 38% lowest valuations
Cheaper than usual
Market cap
9.4Md AUD
Financial strength
3.2/10Cash covers 11.2% of the debt, net debt/EBITDA 2.7x.
Net debt / EBITDA
2.7x
Tight
Gearing (net debt / equity)
61.06%
Tight
Cash
654M AUD
Cash / market cap
6.94%
Tight
Cash / total debt
11.19%
Stretched
Net debt
5.2Md AUD
Equity
8.5Md AUD
Closed daily candles, 2 years
Last close on September 24, 2026: 18.91 AUD
- MM2019.36
- MM5020.84
- MM20021.04
- RSI 1436.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.55%
200-day average slope, 3 months
-1.36%
50-day average slope, 1 month
-2.93%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.62 % per day
Volatility change
-1.83%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 1.21 (11) | 1.22 (16) | 11 110 (16) | 1 964 (16) | 593 (13) |
Amounts in millions of AUD, EPS in AUD per share. In brackets, the number of analysts. Consensus as of September 22, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CI | 7.0 | 7.1 | 70.9Md USD | 11.1x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -8.0 % | ||
| 2 | LH | 6.7 | 5.9 | 24.7Md USD | 25.1x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 10.4 % | ||
| 3 | CVS | 6.6 | 5.9 | 110Md USD | 22.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 10.9 % | ||
| 4 | DVA | 6.5 | 6.4 | 11.7Md USD | 15.4x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 32.3 % | ||
| 5 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 6 | DGX | 6.4 | 5.7 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 7 | FME | 5.3 | 6.7 | 12.0Md USD | 11.8x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -10.0 % | ||
| 8 | SHL | 5.3 | 5.9 | 6.6Md USD | 15.3x | 5.6 % | 8.9 % | 4.6 % | 2.7x | 8.2 % | -13.8 % | ||
| 9 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % |
